Lakeshore biopharma to hold an extraordinary general meeting on july 25, 2024, pursuant to shareholders' requisition

Gaithersburg, md. , july 5, 2024 /prnewswire/ -- lakeshore biopharma co., ltd (nasdaq: lsb) ("lakeshore biopharma" or the "company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the company received a shareholders' requisition dated june 14, 2024, issued by certain shareholders of the company holding shares which carry in aggregate not less than 10% of all votes attaching to all issued and outstanding shares of the company, including yi zhang, all brilliance investments limited, apex pride global limited, hopeful world company limited, and acton town international limited (together, the "requisitioning shareholders"), requesting the directors of the company to convene an extraordinary general meeting (the "egm") of the company (the "requisition") to provide explanations to the shareholders of the company on matters as described below: the circumstances leading to the filing of the united states securities and exchange commission form 6-k report, filed on june 10, 2024 (the "sec report"), including the reasons for the resignation of each of the former directors specified in the sec report.
GM Ratings Summary
GM Quant Ranking